Chemours (NYSE:CC) had its target price raised by equities research analysts at Jefferies Group to $66.00 in a research report issued to clients and investors on Monday, The Fly reports. The brokerage currently has a “buy” rating on the specialty chemicals company’s stock. Jefferies Group’s target price points to a potential upside of 27.31% from the stock’s current price.

Other analysts also recently issued reports about the stock. UBS raised shares of Chemours from a “sell” rating to a “neutral” rating and upped their price objective for the company from $36.00 to $50.00 in a report on Monday, August 7th. Argus reaffirmed a “buy” rating and issued a $55.00 price objective (up from $50.00) on shares of Chemours in a report on Thursday, August 10th. Zacks Investment Research downgraded shares of Chemours from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 12th. Barclays increased their price target on shares of Chemours from $55.00 to $58.00 and gave the stock an “overweight” rating in a report on Monday, November 6th. Finally, BidaskClub raised shares of Chemours from a “hold” rating to a “buy” rating in a report on Thursday, August 24th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Chemours presently has an average rating of “Buy” and an average target price of $54.56.

Shares of Chemours (CC) opened at $51.84 on Monday. The company has a market cap of $9,598.86, a price-to-earnings ratio of 18.38, a PEG ratio of 0.90 and a beta of 3.38. The company has a quick ratio of 1.63, a current ratio of 2.19 and a debt-to-equity ratio of 5.07. Chemours has a twelve month low of $20.76 and a twelve month high of $58.08.

Chemours (NYSE:CC) last released its quarterly earnings data on Thursday, November 2nd. The specialty chemicals company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.01 by $0.11. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.59 billion. Chemours had a net margin of 4.86% and a return on equity of 116.80%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.61 EPS. sell-side analysts predict that Chemours will post 3.73 earnings per share for the current fiscal year.

In other Chemours news, insider E Bryan Snell sold 11,878 shares of the company’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $53.25, for a total transaction of $632,503.50. Following the completion of the transaction, the insider now directly owns 63,063 shares in the company, valued at $3,358,104.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David C. Shelton sold 19,000 shares of the company’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $53.68, for a total transaction of $1,019,920.00. The disclosure for this sale can be found here. Insiders have sold 63,183 shares of company stock worth $3,361,716 over the last three months. 1.14% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of CC. AJO LP acquired a new position in Chemours during the second quarter worth $49,809,000. TIAA CREF Investment Management LLC raised its position in Chemours by 126.5% during the second quarter. TIAA CREF Investment Management LLC now owns 1,789,112 shares of the specialty chemicals company’s stock worth $67,843,000 after acquiring an additional 999,380 shares during the period. Sirios Capital Management L P acquired a new position in Chemours during the second quarter worth $37,430,000. FMR LLC raised its position in Chemours by 6.1% during the second quarter. FMR LLC now owns 15,830,411 shares of the specialty chemicals company’s stock worth $600,289,000 after acquiring an additional 905,038 shares during the period. Finally, Old Mutual Global Investors UK Ltd. acquired a new position in Chemours during the second quarter worth $33,541,000. Institutional investors own 74.42% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/04/chemours-cc-price-target-raised-to-66-00-at-jefferies-group.html.

Chemours Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

The Fly

Analyst Recommendations for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.